Floatz Rating
B62/100
Confidence
Indicative
Sponsor
University of Washington
Modality
protein_peptide
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05242965CT.gov A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05269381CT.gov Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT00569296CT.gov Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT00398138CT.gov Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma | — | Completed | — | — | — |
NCT00514215CT.gov Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer | — | Completed | — | — | — |
NCT00128622CT.gov Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer | — | Completed | — | — | — |
NCT00098917CT.gov Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT00006012CT.gov Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00023985CT.gov Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00005630CT.gov Vaccine Therapy and Sargramostim in Treating Patients With Non-small Cell Lung Cancer | — | Completed | — | — | — |
Show 10 more trialsShow fewer
NCT00005023CT.gov Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer | — | Completed | — | — | — |
NCT00003313CT.gov Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT00003657CT.gov High-dose ICE With Amifostine | — | Completed | — | — | — |
NCT00003269CT.gov Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors | — | Completed | — | — | — |
NCT00003125CT.gov Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors | — | Completed | — | — | — |
NCT00019331CT.gov Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors | — | Completed | — | — | — |
NCT00011921CT.gov Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT00003002CT.gov HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT00019084CT.gov Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer | — | Completed | — | — | — |
NCT00002475CT.gov Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivestim (this asset) | University of Washington | P3 | B · 62 |
| Cis-Diamminedichloroplatinum Ii | University of Vermont | P4 | BB |
| Carboplatin | SystImmune Inc. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Etoposide | SystImmune Inc. | P3 | BB |
| Nivolumab | University of Chicago | P4 | BB |
| Propofol | Kaohsiung Medical University Chung-Ho Memorial Hospital | P4 | BB |
| Vinorelbine Ditartrate | Alliance for Clinical Trials in Oncology | P3 | BB |
| Vinblastine | Intensity Therapeutics, Inc. | P3 | BB |
+42 more in the Lung Cancer cohort
Other indications for Nivestim
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Burkitt Lymphoma | — | P4 | BBB · 78 |
| Neutropenia | — | P4 | BBB · 76 |
| Mycosis Fungoides | — | P4 | BBB · 75 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nivestim in Lung Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/n-met-g-csf-lung-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →